Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma

Correction to: Mol Cancer (2019) 18:141

https://doi.org/10.1186/s12943-019-1064-5

Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 3; specifically the left hand side of Fig. 3d.

Fig. 3.

PVT1 suppression by PVT1 ASOs inhibits EAC cells growth in vitro and in vivo. a PVT1 expression in EAC cell lines (FLO1, SK-GT-4, JHESO, and OE19) and normal esophageal epithelial cell line HET-1A were determined by realtime qPCR analysis. b PVT1 expression was analyzed by qPCR in PVT1 ASOs treated EAC cell lines. PVT1 specific antisense oligonucleotides (ASO4 and ASO5) reduced PVT1 expression in dose-dependent manner in three EAC cell lines. c and d. Inhibition of PVT1 by ASOs significantly suppressed colony formation (c) and decreased cell invasion (d) in both JHESO and OE19 cells in two individual PVT1 ASOs respectively. e Average tumor volume in mice that treated with PVT1 ASO4 or control ASO via subcutaneous injection for 3 weeks (left). Actual tumor weights were retrieved from the mice at the termination of the experiment (middle). Representative tumors after scarified were shown (right). f The expression of PVT1 in mouse tumor tissues measured by qPCR has been shown significant reduction upon treatment with PVT1 ASO4 compared to the control group. Error bars, mean ± SEM. *, P < 0.05; **, P < 0.01

The corrected figure is given below. The correction does not have any effect on the results or conclusions of the paper.